MarketInOut Stock Screener Log In | Sign Up

AnaptysBio Inc

IEX • Healthcare • Biotechnology • Quote as of 10/30/2026
AnaptysBio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization1,444.31 mln
Float27.92 mln
Earnings Date11/10/2026

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

2.21
Highly suspicious

1-Year Forecast

87.25
Transformational upside

Relative Strength

76 / 100
Strongly outperforming

Debt / Equity

25.47
Extremely leveraged

Pre-Tax Margin

25%
Strong margin

Business Description

AnaptysBio Inc. is a San Diego-based biotechnology company working to develop treatments for autoimmune and inflammatory conditions. Its pipeline includes several promising drug candidates at various stages of clinical testing, targeting diseases such as rheumatoid arthritis, psoriasis, celiac disease, and certain cancers. The company works alongside partners GSK and Vanda to advance its research programs from early discovery through clinical development.

Key Fundamentals

EPS-0.96
ROE2,515
RPS3.66
ROIC201
ROA56.62
Interest Cover1.61
EBITDA, mln145
EV / EBITDA10.94
EV / EBIT11.10
Revenue, mln238
EV / Revenue6.69

Quote Details

Last 48.29
Change -0.35 (-0.72%)
Open 48.68
Volume 196,855
Turnover 9,506,128
Average Volume 380,204

Financial Ratios

Pre-Tax Profit Margin25
Leverage Ratio29.95
Current Ratio5.61
Price / Book138
Price / Tangible Book138
Price / Cash Flow79.16
Price / Free Cash Flow129
Debt / Equity25.47
Price / Sales6.23

Financial Strength

Altman Z-Score2.63
Piotroski F-Score 5 / 9
Beneish M-Score2.21
Price to Graham Number6.90
1-Year Target Price87.25
Short Ratio9.41
Short % of Float39.67

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -0.9% 35 / 100   
1 Month -0.7% 46 / 100   
2 Months -9.92% 29 / 100   
6 Months -27.67% 18 / 100   
1 Year 101% 96 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog